【摘要】 目的探究茶碱缓释片联用孟鲁司特治疗咳嗽变异性哮喘的临床疗效及安全性。方法 84例咳嗽变异性哮喘患者,根据计算机随机分为常规组和实验组。每组42例。常规组患者单纯给予口服茶碱缓释片治疗,实验组在常规组基础上加用口服孟鲁司特治疗,观察比较两组患者的临床疗效、症状改善时间和不良反应发生情况。结果实验组患者治疗总有效率95.24%高于常规组的76.19%,差异具有统计学意义(P<0.05);实验组患者的咳嗽缓解时间(5.20±1.55)d、咳嗽消失时间(7.35±1.75)d均短于常规组的(7.45±1.75)、(9.20±1.85)d,差异具有统计学意义(P<0.05);实验组不良反应发生率4.76%明显低于常规组的21.43%,差异具有统计学意义(P<0.05)。结论对咳嗽变异性哮喘患者给予茶碱缓释片+孟鲁司特进行治疗,安全性较高,便于患者临床症状的改善,值得推荐。更多还原

【Abstract】 Objective To investigate the clinical efficacy and safety of theophylline sustained release tablets combined with montelukast in the treatment of cough variant asthma. Methods A total of 84 cough variant asthma patients were divided into conventional group and experimental group by computer random method, with 42 cases in each group. The conventional group was treated with theophylline sustained-release tablets only, and the experimental group was treated with montelukast on the basis of the conventional group. The clinical efficacy, symptom improvement time and occurrence of adverse reactions was observed and compared between the two groups. Results The total effective rate of treatment was 95.24% in the experimental group, which was higher than 76.19% in conventional group, and the difference was statistically significant(P<0.05). The cough remission time(5.20±1.55) d and cough disappearance time(7.35±1.75) d in the experimental group was shorter than(7.45±1.75) and(9.20±1.85) d in the conventional group, and their difference was statistically significant(P<0.05). The incidence of adverse reactions 4.76% in the experimental group was lower than 21.43% in the conventional group, and the difference was statistically significant(P<0.05). Conclusion Theophylline sustained release tablets+montelukast shows high safety for patients with cough variant asthma, and it is convenient for the improvement of clinical symptoms. It is worthy of recommendation.更多还原